ETFs Alnylam Pharmaceuticals, Inc.

ALNY

US02043Q1076

Name	Weight	AuM	1st Jan change
FIRST TRUST NYSE ARCA BIOTECHNOLOGY ETF - CAD	5.08%	1 M€	-.--%	-
FIRST TRUST ALPHADEX U.S. HEALTH CARE SECTOR INDEX ETF - CAD	1.78%	6 M€	0.00%	-
FIRST TRUST ALPHADEX U.S. HEALTH CARE SECTOR INDEX ETF - CAD HEDGED	0.77%	3 M€	-4.30%	-
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY	0.57%	21 M€	+0.33%	-
LYXOR MSCI USA ESG CLIMATE TRANSITION CTB (DR) UCITS ETF - ACC - USD	0.25%	0 M€	-.--%	-
LYXOR MSCI USA ESG LEADERS EXTRA (DR) UCITS ETF - ACC - USD	0.13%	0 M€	-.--%	-
AMUNDI MSCI USA ESG LEADERS SELECT - UCITS ETF DR (C) - USD	0.13%	0 M€	-.--%	-
HSBC MSCI USA UCITS ETF - USD	0.07%	38 M€	+0.36%	-
VANGUARD US TOTAL MARKET SHARES INDEX ETF	0.07%	293,477 M€	-3.35%	-
LEVERAGE SHARES PLC - 3X LONG TOTAL WORLD ETP	0.05%	1 M€	-.--%	-
AMUNDI MSCI WORLD CLIMATE PARIS ALIGNED PAB UCITS ETF DR (C) - USD	0.05%	0 M€	-.--%	-
LYXOR MSCI WORLD CLIMATE CHANGE (DR) UCITS ETF - ACC - USD	0.04%	0 M€	-.--%	-
AMUNDI INDEX MSCI WORLD - UCITS ETF DR (C) - EUR	0.04%	0 M€	-.--%	-
AMUNDI INDEX MSCI WORLD UCITS ETF DR (D) - EUR	0.04%	0 M€	-.--%	-

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. In addition, the Company develops Cemdisiran to treat complement-mediated diseases, Belcesiran for the treatment of alpha-1 liver disease, Elebsiran, Zilebesiran, ALN-APP, ALN-HSD, Fitusiran, and others.

Employees

2,230

Sector

Pharmaceuticals

Calendar

07-30 - Q2 2025 Earnings Release (Projected)

More about the company

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

312.32USD

Average target price

320.88USD

Spread / Average Target

+2.74%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 20:59:23 18/06/2025 BST			5-day change	1st Jan Change
312.09 ^USD	+1.09%		+4.52%	+32.63%

06-18	Alnylam Announces Promotion of Pushkal Garg as Executive Vice President and Chief Research and Development Officer	CI
06-09	Alnylam Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 09:20 AM